Business / Finance

RSS

AIT, BioVendor and SCIENION partner to develop in-vitro diagnostic test for colon cancer

The AIT Austrian Institute of Technology, BioVendor and SCIENION today announced that the three companies will partner on the development of an in-vitro diagnostic test for colon cancer. The innovative test kit shall identify cancer at an early stage based on tumor autoantibody biomarkers.

24 Sep 2014

Celgene Global Health, DNDi expand partnership to identify new drug candidates for NTDs

Celgene Global Health, a division of Celgene Corporation, and the Drugs for Neglected Diseases initiative strengthen their collaboration with a four-year Research Collaboration Agreement to identify and optimize new drug candidates for the treatment of neglected tropical diseases (NTDs).

24 Sep 2014

ImmunoCellular signs licensing agreement with Caltech to develop antigen-specific T-cell technology

ImmunoCellular Therapeutics, Ltd. announced today that it has established a licensing agreement with the California Institute of Technology for exclusive rights to novel technology for the development of certain antigen specific T-cell immunotherapies for the treatment of cancer.

24 Sep 2014

Avalon Ventures, GSK jointly launch two new early-stage life science companies

Avalon Ventures today announced the launch of two new companies formed through its collaboration with GlaxoSmithKline to fund and launch up to 10 early-stage life science companies.

23 Sep 2014

Arthur J. Gallagher & Co. announces acquisition of The Benfield Group

Arthur J. Gallagher & Co. today announced the acquisition of the healthcare consulting firm, The Benfield Group. Headquartered in St. Louis, the firm also has offices in Chicago, Washington, D.C. and Atlanta.

23 Sep 2014

Propanc, Southridge Partners enter into equity purchase agreement

Propanc Health Group Corporation, an emerging healthcare company that focuses on the development of new and proprietary treatments for cancer patients, is pleased to announce it has executed an equity purchase agreement (the "EPA") with Southridge Partners II, L.P., an institutional investor, in the amount of $5 million, which will create significant growth capital for Propanc, enabling the execution of its business plan, on favorable terms.

23 Sep 2014

Neogen's first quarter net income increases 13%

Neogen Corporation announced today that net income for the first quarter of its 2015 fiscal year, which ended Aug. 31, was $8,883,000 — a 13% increase compared to net income of $7,839,000 in the first quarter of last year.

22 Sep 2014

Seward achieves ISO14001 certification for minimising environmental impact

Seward Ltd., manufacturer of the world leading range of original Stomacher paddle blenders and accessories used in sample preparation for microbiological analysis, has received certification for ISO14001.

19 Sep 2014

PCI acquires Biotec Services International

PCI is pleased to announce it has acquired Biotec Services International. Biotec is a leading provider of Clinical Trial Services and Temperature Controlled Pharmaceutical Services headquartered in Bridgend, Wales in the United Kingdom.

19 Sep 2014

Providence Service to acquire CCHN Group Holdings

The Providence Service Corporation, a leader in the management and provision of human social services, innovative global employment services and non-emergency transportation through a variety of government-sponsored programs, announced today that it has entered into an agreement to acquire CCHN Group Holdings, Inc. ("Matrix Medical Network" or "Matrix"), a Scottsdale, Arizona provider of in-home health assessment and care management services and a portfolio company of Welsh, Carson, Anderson & Stowe XI, L.P. ("Welsh Carson").

18 Sep 2014

Zimmer, MiMedx ink distribution agreement

MiMedx Group, Inc., an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has entered into a distribution agreement with Zimmer, Inc.

18 Sep 2014

Sigma-Aldrich enters into new gene editing partnership with U-M Medical School's Vector Core

Sigma-Aldrich Corporation announced today it has entered into a new gene editing partnership with the University of Michigan Medical School's Vector Core. Under the partnership, Sigma-Aldrich will provide the Vector Core with Sigma CRISPR technology, experimental design consultation, and dedicated gene editing bioinformaticians.

18 Sep 2014

Sanofi, MyoKardia partner to develop targeted therapeutics for cardiomyopathies

Sanofi and MyoKardia, Inc., a privately-held company leading the development of precision therapies for genetic heart disease, announced today a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease.

18 Sep 2014

Twinlab Consolidation becomes wholly-owned subsidiary of Twinlab Consolidated Holdings

As announced on August 11, 2014, Twinlab Consolidation Corporation completed its first transaction with the acquisition of Twinlab Corporation. Today, TCC announces the successful completion of its merger into Twinlab Consolidated Holdings Inc., resulting in TCC becoming a wholly-owned subsidiary of TLCC.

17 Sep 2014

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I).

17 Sep 2014

Denovo gains all rights from Lilly to develop, manufacture and commercialize enzastaurin drug

Denovo Biopharma, LLC, today announced that it has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Company. Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data, and information.

16 Sep 2014

Lilly, AstraZeneca partner to co-develop and commercialize potential Alzheimer's disease treatment

Eli Lilly and Company and AstraZeneca today announced an agreement to co-develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease.

16 Sep 2014

New ACD European subsidiary aims to provide faster, enhanced support for local customers

Advanced Cell Diagnostics Inc., a technology and market leader in the field of molecular pathology and developer of cell and tissue-based analysis tools, has announced the establishment of a European subsidiary which will start business in October 2014.

From Advanced Cell Diagnostics 16 Sep 2014

Danaher signs definitive transaction agreement with Nobel Biocare

Danaher Corporation has entered into a definitive transaction agreement with Nobel Biocare Holding AG pursuant to which Danaher Corporation or one of its direct or indirect subsidiaries ("Danaher") will commence a tender offer for all publicly held registered shares of Nobel Biocare in an all-cash transaction valued at approximately $2.2 billion.

From Danaher 15 Sep 2014

ChromaDex signs NIAGEN supply agreement with Healthy Directions

ChromaDex Corp., an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that it has entered into an ingredient supply agreement with Healthy Directions, a direct-to-consumer nutritional supplement retailer and wholly-owned subsidiary of Helen of Troy Limited.

11 Sep 2014

Business / Finance

AIT, BioVendor and SCIENION partner to develop in-vitro diagnostic test for colon cancer

Celgene Global Health, DNDi expand partnership to identify new drug candidates for NTDs

ImmunoCellular signs licensing agreement with Caltech to develop antigen-specific T-cell technology

Avalon Ventures, GSK jointly launch two new early-stage life science companies

Arthur J. Gallagher & Co. announces acquisition of The Benfield Group

Propanc, Southridge Partners enter into equity purchase agreement

Neogen's first quarter net income increases 13%

Seward achieves ISO14001 certification for minimising environmental impact

PCI acquires Biotec Services International

Providence Service to acquire CCHN Group Holdings

Zimmer, MiMedx ink distribution agreement

Sigma-Aldrich enters into new gene editing partnership with U-M Medical School's Vector Core

Sanofi, MyoKardia partner to develop targeted therapeutics for cardiomyopathies

Twinlab Consolidation becomes wholly-owned subsidiary of Twinlab Consolidated Holdings

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

Denovo gains all rights from Lilly to develop, manufacture and commercialize enzastaurin drug

Lilly, AstraZeneca partner to co-develop and commercialize potential Alzheimer's disease treatment

New ACD European subsidiary aims to provide faster, enhanced support for local customers

Danaher signs definitive transaction agreement with Nobel Biocare

ChromaDex signs NIAGEN supply agreement with Healthy Directions

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Latest News